Dako and Quintiles form alliance to speed development of personalized medicine
(Thomson Reuters ONE) -
Dako, a Danish-based world leader in tissue-based cancer diagnostics, and
Quintiles, the world's leading biopharmaceutical services companies, today
announced a strategic alliance to advance personalized medicine by collaborating
on the co-development of targeted therapies and companion diagnostics.
Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-
diagnostic development services and companion diagnostic products. The first
such collaboration will support AstraZeneca in the development of one of its
leading oncology compounds.
"Quintiles and Dako share the same goals for speed, quality and efficiency,"
said Thomas Wollman, Senior Vice President, Quintiles Global Central
Laboratories. "By pairing our core competencies in translational medicine,
biomarker discovery and managing clinical trials with Dako's expertise in
companion diagnostics, we can help physician investigators select the right
patients for the right clinical trials, thereby accelerating the development of
personalized oncology therapies for our customers in the New Health landscape."
As part of the alliance, Dako will develop cancer diagnostic tests, and
Quintiles will conduct the tests as part of the clinical validation. Both Dako
and Quintiles will continue to work independently with biopharmaceutical
companies and service providers in the industry.
"I'm excited about this collaboration. It is designed to help biopharma
companies streamline the development of safer, more effective targeted
therapies," said Dako CEO Lars Holmkvist. "By combining highly accurate,
reliable diagnostic tests and results with the proper management of critical
patient data, we can help companies advance their oncology therapies more
rapidly - with the ultimate goal of benefiting patients."
Today, Quintiles develops proprietary and novel biomarker tests analyzing genes
and proteins that affect cancer cell growth and mutation, and performs these
assays at labs in the United States, Scotland and China. Quintiles has the
largest and now entirely CAP-accredited central laboratory network in the world,
with wholly owned facilities in the United States, Europe, South Africa, India,
China, Singapore and Japan, and a tightly controlled network of affiliate
laboratories in Argentina and Brazil.
Dako is constantly looking for opportunities to improve cancer diagnostics. This
includes forming partnerships with companies with complementing technologies as
well as entering into collaborations with pharmaceutical companies to develop
diagnostic tests for specific therapies. Dako has expanded its reach into the
emerging markets and opened subsidiaries in China and Brazil earlier this year.
Media contact
Dako:
Lene Christoffersen
+45 40 74 87 82
lene.christoffersen(at)dako.com
Quintiles:
Lindsay Singler, Media Relations
+1 919 998-7968
lindsay.singler(at)quintiles.com
Greg Connors, Investor Relations
+1 919 998-2000
invest(at)quintiles.com
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make precise diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1000 people and being present in more than 80 countries, Dako covers essentially
all of the anatomic pathology markets globally. Dako is owned by a private
equity fund, EQT.www.dako.com
About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company
offering clinical, commercial, consulting and capital solutions worldwide. The
Quintiles network of more than 20,000 engaged professionals in 60 countries
works with an unwavering commitment to patients, safety and ethics. Quintiles
helps biopharmaceutical companies navigate risk and seize opportunities in an
environment where change is constant. For more information, please
visitwww.quintiles.com.
[HUG#1457652]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 01.11.2010 - 14:20 Uhr
Sprache: Deutsch
News-ID 48265
Anzahl Zeichen: 5014
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako and Quintiles form alliance to speed development of personalized medicine"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
